EUVIMEDSkopri EUVIMED
Fallbericht

Cutaneous FUS::TFCP 2‐Rearranged Rhabdomyosarcoma Initially Misdiagnosed as ALK ‐Rearranged Mesenchymal Neoplasm: A Case Report

Daigo Shiraishi, Kenji Murata, Junya Shimizu, Yasutaka Murahashi, Taro Sugawara, Shintaro Sugita iD, Makoto Emori iD, Atsushi Teramoto

Journal of Cutaneous Pathology · 2025

DOI: 10.1111/cup.14869 ↗

At a glance

Fallbericht in Journal of Cutaneous Pathology, 2025. Written by Daigo Shiraishi and 7 co-authors. Institution: Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan. Major MEDLINE topics: Rhabdomyosarcoma, RNA-Binding Protein FUS, Skin Neoplasms, Oncogene Proteins, Fusion. 12 references. Funded by: Japan Society for the Promotion of Science.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

FUS::TFCP 2‐rearranged rhabdomyosarcoma is a recently identified malignant neoplasm characterized by immunohistochemical evidence of the co‐expression of rhabdomyoblastic markers and ALK. Herein, we report a case of cutaneous spindle cell/sclerosing rhabdomyosarcoma with FUS::TFCP 2 fusion that was initially interpreted as an ALK‐rearranged mesenchymal neoplasm in a 43‐year‐old male due to negative desmin expression, a rhabdomyoblastic marker. RNA sequencing was performed to detect ALK fusion counterparts; however, no ALK counterpart fusion was observed, and FUS::TFCP 2 fusion was detected. Myogenin was negative, but MyoD1 was positive. Detection of FUS signals using FISH led to the diagnosis of FUS::TFCP 2‐rearranged rhabdomyosarcoma. In cases of ALK positivity and spindle cell or epithelioid cell morphology, FUS::TFCP 2‐rearranged rhabdomyosarcoma should be considered in the differential diagnosis using staining for rhabdomyoblastic markers other than desmin.

Subjects

MeSH terms (MEDLINE)

RhabdomyosarcomaRNA-Binding Protein FUSSkin NeoplasmsOncogene Proteins, FusionRepressor ProteinsHumansMaleAdultAnaplastic Lymphoma KinaseGene RearrangementDiagnostic ErrorsDiagnosis, DifferentialIn Situ Hybridization, FluorescenceDNA-Binding ProteinsTranscription Factors

Author keywords

ALKFUSTFCP2fusionrhabdomyoblastic makerrhabdomyosarcoma

Substances

RNA-Binding Protein FUSAnaplastic Lymphoma KinaseFUS protein, humanALK protein, humanOncogene Proteins, FusionTFCP2 protein, humanRepressor ProteinsDNA-Binding ProteinsTranscription Factors

Authors and institutions

  • Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.

ORCID profiles: Shintaro Sugita, Makoto Emori

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Shiraishi, D., Murata, K., Shimizu, J., Murahashi, Y., Sugawara, T., Sugita, S., Emori, M., & Teramoto, A. (2025). Cutaneous FUS::TFCP 2‐Rearranged Rhabdomyosarcoma Initially Misdiagnosed as ALK ‐Rearranged Mesenchymal Neoplasm: A Case Report. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14869

Vancouver

Shiraishi D, Murata K, Shimizu J, Murahashi Y, Sugawara T, Sugita S, et al. Cutaneous FUS::TFCP 2‐Rearranged Rhabdomyosarcoma Initially Misdiagnosed as ALK ‐Rearranged Mesenchymal Neoplasm: A Case Report. Journal of Cutaneous Pathology. 2025. doi:10.1111/cup.14869

BibTeX
@article{Shiraishi2025,
  author = {Shiraishi, Daigo and Murata, Kenji and Shimizu, Junya and Murahashi, Yasutaka and Sugawara, Taro and Sugita, Shintaro and Emori, Makoto and Teramoto, Atsushi},
  title = {Cutaneous FUS::TFCP 2‐Rearranged Rhabdomyosarcoma Initially Misdiagnosed as ALK ‐Rearranged Mesenchymal Neoplasm: A Case Report},
  journal = {Journal of Cutaneous Pathology},
  year = {2025},
  doi = {10.1111/cup.14869}
}
Start for free →